WeiqiangZhaoMDPhD, FCAP
Pathology • Columbus, OHHematopathology, Molecular Genetics, Anatomic Pathology, Clinical Pathology
Professor of Pathology, Ohio State University College of Medicine Columbus, OH Medical Director, James Molecular Laboratory at Polaris Medical Director, Cytogenetics Lab, James Cancer Center/Hospital
Dr. Zhao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2001 Polaris Pkwy
Columbus, OH 43240Phone+1 614-366-7015Fax+1 614-293-7013
Summary
- Dr. Weiqiang Zhao is a pathologist in Columbus, OH affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute. He received his medical degree from Hunan Medical University and has been in practice 35 years. He also speaks multiple languages, including Chinese (Mandarin). He specializes in hematopathology, molecular genetics, anatomic pathology, and clinical pathology and is experienced in the diagnosis of acute myeloid leukemia, lymphoma, non-small cell lung cancer, acute lymphoblastic leukemia, and myeloproliferative neoplasms.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Molecular Genetic Pathology, 2006 - 2007
Tulane UniversityFellowship, Hematopathology, 2005 - 2006- Tulane UniversityResidency, Pathology-Anatomic and Clinical, 2003 - 2005
Hunan Medical UniversityClass of 1982
Certifications & Licensure
OH State Medical License 2007 - 2025
LA State Medical License 2004 - 2007- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- 744 citationsRadiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialMaura L. Gillison, Andy Trotti, Jonathan Harris, Avraham Eisbruch, Paul M. Harari
Lancet. 2019-01-05 - 1714 citationsTargeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger
The New England Journal of Medicine. 2013-07-03 - 559 citationsThree-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.John C. Byrd, Richard R. Furman, Steven Coutre, Jan A. Burger, Kristie A. Blum
Blood. 2015-04-16
Journal Articles
- Givinostat, A Type II Histone Deacetylase Inhibitor, Induces Potent Caspase-Dependent Apoptosis in Human Lymphoblastic Leukemia.Li Ying, K Zhao, C Yao, S Kahwash, Y Tang, G Zhang, K Patterson, Qi-En Wang, W Zhao, Genes & Cancer, 9/24/2016
Press Mentions
Multi-Gene Testing Could Detect More Hereditary Cancer SyndromesMay 10th, 2021
Committees
- Committee Scientific Expert, Committee to Review the Styrene Assessment in the National Toxicology Program 12th Report on Carcinogens, National Academies, Board of Environmental Studies and Toxicology, Washington DC. 2013 - 2014
Professional Memberships
- Member
- Member
- Fellow
- Fellow
Other Languages
- Chinese (Mandarin)
External Links
- Dr. Zhaohttps://pathology.osu.edu/ext/faculty/zhao.html
- OSU Molecular Laboratorieshttps://pathology.osu.edu/ext/divisions/Clinical/molpath/default.htm#faculty
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
